To better define the origin of MVs and the cargo they transport, we considered that circulating mutant KRAS DNA varies according to tumor response [47], unlike PD-L1 observed in this study, which does not parallel tumor changes, thus ruling out that the increase in PD-L1 in plasma is dependent on the release of biological macromolecules by dying cells as a result of chemotherapy. The gene discussed is KRAS; the disease is neoplasm.